Combination therapy using anti-ssea-4 antibody in combination with therapeutic oncology agents
AssigneeObi Pharma, Inc.
InventorsCheng-Der Tony YU, Jiann-Shiun LAI, Yi-Chien TSAI
Life of this patent
Estimating the term…
Abstract
The present disclosure is generally directed to treatment methods and compositions comprising administering anti-SSEA-4 antibodies; alone or in additive and/or synergistic combination with other therapeutic agents in oncology to enhance therapeutic efficacy whereby the interaction alters the epitope binding of Siglec-9 protein; including human Siglec-9 or a mammalian Siglec-9; wherein the use of such anti-SSEA-4 compositions are efficacious in preventing, reducing risk, or treating an individual with cancer.
Claims20
A method of treating a subject having a cancer cell expressing a SSEA-4 antigen, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an anti-SSEA-4 antibody or a fragment thereof.
A method of activating an innate cytotoxicity immune response by inhibiting binding of a Siglec-9 expressing cytotoxic immune cell bound to a SSEA-4 antigen on a cancer cell, the method comprising contacting the cytotoxic immune cell-cancer cell complex with an antagonist of SSEA-4;
- and disrupting or inhibiting binding of Siglec-9 to SSEA-4.
A method of treating a subject having a cancer cell expressing a SSEA-4 antigen, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an anti-SSEA-4 antibody or a fragment thereof, whereby the binding of Siglec-9 to cancer cells is inhibited.
A method of reducing the binding of Siglec-9 to cancer cells, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an anti-SSEA-4 antibody or a fragment thereof.
A method of treating a subject having a cancer cell expressing a SSEA-4 antigen, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an anti-SSEA-4 antibody or a fragment thereof, whereby the activity of the cytotoxic immune cells is activated.
A method of increasing the activity of the cytotoxic immune cells in a subject having a cancer, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an anti-SSEA-4 antibody or a fragment thereof.
Dependencies are inferred from the claim text.